Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Marcoux

Internal Medicine Pawtucket, RI Medical Doctor

NPI 1730140864 CMS profile 124521

407 East Ave Ste 110, Pawtucket, RI 02860

Open in the dashboard

General payments

$1,972

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Marcoux of Pawtucket, RI is reported in the CMS Open Payments database as having received $1,972 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $540 20
2024 General $426 22
2023 General $364 19
2022 General $200 11
2021 General $225 13
2020 General $16 1
2019 General $202 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Marcoux
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Marcoux were reported at $540. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Marcoux Internal Medicine median Middle half National median
2019 $202 $159 $48–$570 $163
2020 $16 $119 $33–$402 $114
2021 $225 $135 $37–$521 $132
2022 $200 $141 $42–$496 $149
2023 $364 $149 $45–$519 $160
2024 $426 $154 $47–$537 $164
2025 $540 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $344 16 payments
  2. AstraZeneca Pharmaceuticals LP $244 14 payments
  3. Amgen Inc. $192 2 payments
  4. Pfizer Inc. $165 10 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $144 8 payments
  6. GlaxoSmithKline, LLC. $109 6 payments
  7. Novo Nordisk Inc $88 4 payments
  8. Lilly USA, LLC $84 5 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $66 3 payments
  10. Lundbeck LLC $57 3 payments
  11. Other $478 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,797 98 payments
  2. Consulting Fee $175 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $218 10 payments
  2. Prolia $192 2 payments
  3. XIFAXAN $144 8 payments
  4. FARXIGA $137 7 payments
  5. QULIPTA $106 5 payments
  6. TRULANCE $106 6 payments
  7. ELIQUIS $101 6 payments
  8. NURTEC ODT $90 5 payments
  9. SHINGRIX $75 4 payments
  10. Wegovy $69 3 payments
  11. Other $1,316 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 160 drugs

Part D claims

9,886

Median for Internal Medicine: 777

Drug cost

$826,284

Median for Internal Medicine: $73,373

Branded share of claims

18.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 128 $156,301
Ozempic Semaglutide Brand 74 $96,579
Jardiance Empagliflozin Brand 79 $76,067
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 59 $67,486
Farxiga Dapagliflozin Propanediol Brand 54 $54,000
Myrbetriq Mirabegron Brand 77 $53,698
Mounjaro Tirzepatide Brand 42 $47,072
Xarelto Rivaroxaban Brand 22 $30,474
Creon Lipase/Protease/Amylase Brand 22 $28,677
Breo Ellipta Fluticasone/Vilanterol Brand 27 $18,602

The 10 drugs with the highest cost, of 160 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$46,789

Of which drugs: $7,613

Medicare patients

304

Average age 76

Services billed

1,686

131 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 47%
Ischemic heart disease 28%
Diabetes 27%
Chronic kidney disease 27%
Cancer 24%
Osteoporosis 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 48 51 $1
Sarscv2 vac 30mcg trs-suc im 91320 Office 36 39 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $46
$46 — —
UBRELVY
  • AbbVie, Inc. $37
$37 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $28
$28 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $17
  • PFIZER INC. $10
$28 128 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record